Entos Pharmaceuticals

Entos Pharmaceuticals is a biotechnology company pioneering the development of next-generation genetic medicines through its proprietary Fusogenix drug delivery platform. Headquartered in Canada, Entos focuses on solving one of the most critical challenges in genetic medicine: the safe and effective delivery of therapeutic payloads—including DNA, RNA, and proteins—directly into cells. The Fusogenix platform utilizes a novel proteo-lipid vehicle (PLV) technology that facilitates the direct fusion of therapeutic molecules with the target cell membrane, enabling efficient intracellular delivery without triggering immune responses or causing toxicity.

Entos is advancing a broad pipeline of therapeutics that target cancer, infectious diseases, and rare genetic disorders. Their approach offers scalable, non-viral solutions that overcome the limitations of traditional delivery systems such as viral vectors and lipid nanoparticles (LNPs). In addition to its internal programs, Entos collaborates with global pharmaceutical companies and research institutions to co-develop and apply its Fusogenix platform across a wide range of therapeutic areas.

The company has also made headlines for its work in developing DNA-based COVID-19 vaccine candidates and continues to explore applications in personalized medicine and next-gen vaccines. With an emphasis on innovation, safety, and efficacy, Entos Pharmaceuticals is poised to be a major player in the evolving field of genetic medicine.

Keywords: genetic medicines, drug delivery, Fusogenix, proteo-lipid vehicle, Entos Pharmaceuticals, cancer therapy, RNA delivery, DNA therapeutics, non-viral delivery, biotechnology, gene therapy, vaccine development, rare diseases, intracellular delivery, Canadian biotech.